Evaluation of the impact of timing of pegfilgrastim administration on incidence of febrile neutropenia in elderly patients with B-cell non-Hodgkin lymphomas receiving R-CHOP-21

Click to increase image sizeClick to decrease image size

Ethical approval

The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, or the National Institutes of Health.

Acknowledgements

Study data were collected and managed using REDCap electronic data capture tools hosted at Partners Healthcare13. REDCap (Research Electronic Data Capture) is a secure, web-based application designed to support data capture for research studies, providing (1) an intuitive interface for validated data entry; (2) audit trails for tracking data manipulation and export procedures; (3) automated export procedures for seamless data downloads to common statistical packages; and (4) procedures for importing data from external sources.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was conducted with support from Harvard Catalyst | The Harvard Clinical and Translational Science Center [National Center for Advancing Translational Sciences, National Institutes of Health Award UL 1TR002541] and financial contributions from Harvard University and its affiliated academic healthcare centers.